JP6935873B2 - ５−ｈｔ１ａ受容体によってコントロールされるセロトニン作動性制御に対する感受性が高い障害を処置するための新規化合物 - Google Patents

５−ｈｔ１ａ受容体によってコントロールされるセロトニン作動性制御に対する感受性が高い障害を処置するための新規化合物 Download PDF

Info

Publication number
JP6935873B2
JP6935873B2 JP2019520488A JP2019520488A JP6935873B2 JP 6935873 B2 JP6935873 B2 JP 6935873B2 JP 2019520488 A JP2019520488 A JP 2019520488A JP 2019520488 A JP2019520488 A JP 2019520488A JP 6935873 B2 JP6935873 B2 JP 6935873B2
Authority
JP
Japan
Prior art keywords
compound
iib
nmr
cdcl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019520488A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019519615A (ja
JP2019519615A5 (enExample
Inventor
ヨアンナ・スニエチコフスカ
アダム・ブツキ
エイドリアン・ニューマン−タンクレディ
マーク・アンドリュー・バーニー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurolixis
Universite Jagellonne
Original Assignee
Neurolixis
Universite Jagellonne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurolixis, Universite Jagellonne filed Critical Neurolixis
Publication of JP2019519615A publication Critical patent/JP2019519615A/ja
Publication of JP2019519615A5 publication Critical patent/JP2019519615A5/ja
Application granted granted Critical
Publication of JP6935873B2 publication Critical patent/JP6935873B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/38—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
JP2019520488A 2016-06-24 2017-06-23 ５−ｈｔ１ａ受容体によってコントロールされるセロトニン作動性制御に対する感受性が高い障害を処置するための新規化合物 Active JP6935873B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16305769.8 2016-06-24
EP16305769.8A EP3260452A1 (en) 2016-06-24 2016-06-24 Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-ht1a receptors
PCT/EP2017/065585 WO2017220799A1 (en) 2016-06-24 2017-06-23 Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-ht1a receptors

Publications (3)

Publication Number Publication Date
JP2019519615A JP2019519615A (ja) 2019-07-11
JP2019519615A5 JP2019519615A5 (enExample) 2020-07-30
JP6935873B2 true JP6935873B2 (ja) 2021-09-15

Family

ID=56404042

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019520488A Active JP6935873B2 (ja) 2016-06-24 2017-06-23 ５−ｈｔ１ａ受容体によってコントロールされるセロトニン作動性制御に対する感受性が高い障害を処置するための新規化合物

Country Status (9)

Country Link
US (1) US10562853B2 (enExample)
EP (2) EP3260452A1 (enExample)
JP (1) JP6935873B2 (enExample)
CN (1) CN109563073B (enExample)
AU (1) AU2017281742B2 (enExample)
CA (1) CA3028036A1 (enExample)
DK (1) DK3475268T3 (enExample)
ES (1) ES2831853T3 (enExample)
WO (1) WO2017220799A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119874616B (zh) * 2025-03-28 2025-05-30 四川美域高生物医药科技有限公司 一种有机中间体及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2702211B1 (fr) * 1993-03-04 1995-06-02 Pf Medicament Nouveaux dérivés de la phénoxy-2 éthylamine, leur préparation et leur application en thérapeutique.
FR2755967B1 (fr) 1996-11-21 1999-01-29 Pf Medicament Derives de la pyridin-2-yl-methylamine, leur procede de preparation et leur application comme medicaments
FR2784378B1 (fr) * 1998-10-09 2000-12-29 Pf Medicament Nouveaux derives d'aryl-(4-fluoro-4-[(2-pyridin-2-yl- ethylamino)-methyl]-piperidin-1-yl)-methanone, leur procede de preparation et leur utilisation a titre de medicaments
EP2058306A1 (en) * 2007-11-08 2009-05-13 Schwarz Pharma Ag Heteroaryl-substituted 2-pyridinyl-methylamine derivatives
PL395470A1 (pl) * 2011-06-29 2013-01-07 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Sulfonamidowe pochodne amin alicyklicznych do leczenia chorób osrodkowego ukladu nerwowego

Also Published As

Publication number Publication date
CA3028036A1 (en) 2017-12-28
AU2017281742A1 (en) 2019-01-03
ES2831853T3 (es) 2021-06-09
JP2019519615A (ja) 2019-07-11
EP3475268B9 (en) 2021-04-21
CN109563073A (zh) 2019-04-02
US10562853B2 (en) 2020-02-18
EP3475268B1 (en) 2020-08-19
EP3475268A1 (en) 2019-05-01
EP3260452A1 (en) 2017-12-27
US20190194132A1 (en) 2019-06-27
WO2017220799A1 (en) 2017-12-28
CN109563073B (zh) 2021-12-07
AU2017281742B2 (en) 2021-01-07
DK3475268T3 (da) 2020-10-26

Similar Documents

Publication Publication Date Title
JP5335932B2 (ja) 制癌剤である二置換ピリジン誘導体
JP6254075B2 (ja) カリウムチャネル遮断剤としてのアミン誘導体
ES2883701T3 (es) Agonistas del receptor 2 del péptido formilado de ciclopropil urea y agonistas del receptor 1 del péptido formilado
JP7470058B2 (ja) 複素環化合物
CN114286818B (zh) 作为bet抑制剂的杂环化合物
JP2021522253A (ja) 化合物及びその使用
EA039808B1 (ru) Аминотриазолопиридины в качестве ингибиторов киназ
CN103717593B (zh) 调节激酶的组合物和方法
WO2009110985A2 (en) Amide compounds, compositions and uses thereof
JP2022544714A (ja) 甲状腺ホルモン受容体ベータアゴニスト化合物
JP2003321472A (ja) Ｇｒｋ阻害剤
CN117440955A (zh) 具有食欲素-2受体激动剂活性的取代的酰胺大环化合物
AU2013253541A1 (en) Quinazolinedione derivative
JP7317721B2 (ja) 複素環化合物
JP2017512796A (ja) 置換含窒素複素環誘導体、それを含む医薬組成物及びその抗腫瘍性の適用
CN103037693A (zh) 作为mglur5正向变构调节剂的取代的6-甲基烟酰胺
EA001217B1 (ru) СЕЛЕКТИВНЫЕ β-АДРЕНЕРГИЧЕСКИЕ АГОНИСТЫ
JP6935873B2 (ja) ５−ｈｔ１ａ受容体によってコントロールされるセロトニン作動性制御に対する感受性が高い障害を処置するための新規化合物
JP2013047223A (ja) 医薬
JP2023539336A (ja) Ｇｐｒ５２モジュレーター化合物
TW200404067A (en) New compounds
WO2022240992A1 (en) Heterocyclic trpml1 agonists and uses thereof
HK40007735A (en) Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-ht1a receptors
HK40007735B (en) Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-ht1a receptors
CN118019738A (zh) 作为sting拮抗剂的小分子脲衍生物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200619

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200619

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210611

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210803

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210816

R150 Certificate of patent or registration of utility model

Ref document number: 6935873

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250